CD19 and diffuse large B-cell lymphoma: Immunotherapy has revolutionized the treatment of R/R DLBCL through the introduction of anti‐CD19 antibodies, anti‐CD19 CAR T‐cell (CAR T) therapies, and bispecific CD3/CD20 antibodies (Figure 1).